We have located links that may give you full text access.
Comparing the prognostic performance of iBOX and biopsy-proven acute rejection for long-term kidney graft survival.
American Journal of Transplantation 2024 April 19
Biopsy-proven acute rejection (BPAR) occurs in approximately 10% of kidney transplant recipients in the first year making superiority trials unfeasible. IBOX, a quantitative composite of eGFR, proteinuria, anti-HLA DSA, and + full/- abbreviated kidney histopathology, is a new proposed surrogate endpoint. BPAR's prognostic ability was compared to iBOX in a pooled cohort of 1534 kidney transplant recipients from four datasets, including two prospective randomized controlled trials. Discrimination analyses showed mean c-statistic differences between both iBOX compared to BPAR of 0.25 (95%CI: 0.17, 0.32) for full iBOX and 0.24 (95%CI: 0.16, 0.32) for abbreviated iBOX, indicating statistically significantly higher c-statistic values for the iBOX prognosis of death-censored graft survival. Mean (standard error) c-statistics were 0.81±0.03 for full iBOX, 0.80±0.03 for abbreviated iBOX, and 0.57±0.03 for BPAR. In calibration analyses, predicted graft loss events from both iBOX models were not significantly different from those observed. However, for BPAR, the predicted events were significantly (p<0.01) different (observed 64; predicted: 70 full iBOX; 76 abbreviated iBOX; 173 BPAR). IBOX at one-year post-transplant is superior to BPAR in the first year post-transplant in graft loss prognostic performance, providing valuable additional information facilitating the demonstration of superiority of novel immunosuppressive regimens.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app